140 related articles for article (PubMed ID: 9828911)
1. Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome.
Garcia-Rudaz C; Armando I; Levin G; Escobar ME; Barontini M
Clin Endocrinol (Oxf); 1998 Aug; 49(2):221-8. PubMed ID: 9828911
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a hypothalamic alteration of catecholamine metabolism in polycystic ovary syndrome.
Paradisi R; Grossi G; Venturoli S; Capelli M; Porcu E; Fabbri R; Pasquali R; Flamigni C
Clin Endocrinol (Oxf); 1988 Sep; 29(3):317-26. PubMed ID: 3251670
[TBL] [Abstract][Full Text] [Related]
3. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome.
Rosen GF; Lobo RA
J Clin Endocrinol Metab; 1987 Nov; 65(5):891-5. PubMed ID: 3117832
[TBL] [Abstract][Full Text] [Related]
4. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
5. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
6. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
Berga SL; Yen SS
Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
[TBL] [Abstract][Full Text] [Related]
7. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
8. Changes in brain catecholamine metabolism during bromocriptine treatment in polycystic ovary syndrome.
Paradisi R; Grossi G; Venturoli S; Porcu E; Rocchi G; Pasquali R; Capelli M; Flamigni C
Horm Res; 1993; 39(5-6):223-8. PubMed ID: 8314207
[TBL] [Abstract][Full Text] [Related]
9. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
Barletta C; Vagiri D; Scavo D
Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
[TBL] [Abstract][Full Text] [Related]
10. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575
[TBL] [Abstract][Full Text] [Related]
11. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
Toscano V; Bianchi P; Balducci R; Guglielmi R; Mangiantini A; Lubrano C; Sciarra F
Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
[TBL] [Abstract][Full Text] [Related]
12. Endocrinological meaning of hyperandrogenism in patients with polycystic ovary.
Takahashi K; Eda Y; Kusakari M; Yoshino K; Kitao M
Gynecol Obstet Invest; 1991; 31(1):46-50. PubMed ID: 2010114
[TBL] [Abstract][Full Text] [Related]
13. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.
Holte J; Bergh T; Gennarelli G; Wide L
Clin Endocrinol (Oxf); 1994 Oct; 41(4):473-81. PubMed ID: 7955458
[TBL] [Abstract][Full Text] [Related]
14. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
15. Further evidence concerning catecholamine metabolism in polycystic ovary syndrome following Gn-RH administration.
Yoshino K; Takahashi K; Nishigaki A; Eda Y; Kitao M
Int J Fertil; 1992; 37(2):111-4. PubMed ID: 1349592
[TBL] [Abstract][Full Text] [Related]
16. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome.
Lobo RA; Granger LR; Paul WL; Goebelsmann U; Mishell DR
Am J Obstet Gynecol; 1983 Feb; 145(4):496-503. PubMed ID: 6824043
[TBL] [Abstract][Full Text] [Related]
17. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
19. Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries.
Aono T; Miyazaki M; Miyake A; Kinugasa T; Kurachi K; Matsumoto K
Acta Endocrinol (Copenh); 1977 Aug; 85(4):840-9. PubMed ID: 196471
[TBL] [Abstract][Full Text] [Related]
20. Pituitary-ovarian relationships in polycystic ovary syndrome.
Baird DT; Corker CS; Davidson DW; Hunter WM; Michie EA; Van Look PF
J Clin Endocrinol Metab; 1977 Oct; 45(4):798-801. PubMed ID: 334789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
